GlassScriptPhysician profile
Jimi O Benson
NPI 1477751667
$3,720.99
in general payments reported to CMS, 2019-2025
33 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $145 · 2021: $147 · 2022: $346 · 2023: $631 · 2024: $868 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $675.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $324.31 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $242.86 | 2019 | |
| Abbvie INC. | $231.09 | 2021-2025 | Ubrelvy, Creon, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.41 | 2022-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $206.55 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $204.95 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $196.52 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $195.89 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $164.68 | 2019-2022 | |
| Novo Nordisk INC | $134.15 | 2022-2025 | Wegovy |
| Neurelis, INC. | $131.17 | 2022-2024 | Valtoco |
| Gilead Sciences, INC. | $121.88 | 2019 | |
| Glaxosmithkline, LLC. | $90.46 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $62.21 | 2024 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $61.12 | 2025 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.89 | 2021-2025 | Caplyta |
| Exact Sciences Corporation | $40.67 | 2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $38.87 | 2024-2025 | Ingrezza |
| Boston Scientific Corporation | $37.91 | 2025 | Wavewriter Alpha Prime 16 |
| Pulmonx Corporation | $30.72 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Tempus Ai, INC | $29.34 | 2024 | |
| Microtransponder, INC. | $25.24 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.47 | 2023 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $24.00 | 2021 | |
| Merck Sharp & Dohme LLC | $23.81 | 2023 | Verquvo, Belsomra, Steglatro |
| Grifols USA, LLC | $22.30 | 2024 | Prolastin-C Liquid |
| Abiomed | $21.79 | 2024 | Impella |
| Kyowa Kirin, INC. | $19.77 | 2023 | |
| Baxter Healthcare | $19.43 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Nevro Corp. | $18.02 | 2024 | Senza |
| Vbi Vaccine (Delaware) INC. | $12.84 | 2023 | Prehevbrio |
| Sanofi-Aventis U.S. LLC | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimi Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.